Filing Flows › Entera Bio (ENTX) › Q4 2024
Entera Bio (ENTX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 28, 2025
Entera Bio (ENTX) reported revenue of $82K for the fourth quarter 2024 (Q4 2024) and +95% from the quarter before.
Entera Bio, Q4 2024: revenue $82K, net loss $2.4M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $82K | +95% | — |
| Operating profit | −$2.3M | — | — |
| Net earnings | −$2.4M | — | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $82K in Q4 2024, up 95% from the previous quarter.
Operating costs exceeded revenue by $2.3M, an operating margin of -2850.0%. The quarter ended with a net loss of $2.4M, narrower than the previous quarter's $3.0M loss.
Operating cash flow was −$1.5M. Non-cash charges added back $11K of depreciation and $566K of share-based compensation. Working capital and other items added $314K. Capital expenditures of $3K exceeded it, leaving free cash flow of −$1.5M.
Questions
What was Entera Bio's revenue in the fourth quarter 2024?
Entera Bio (ENTX) reported revenue of $82K for the fourth quarter 2024 (Q4 2024) and +95% from the quarter before.
Source: Entera Bio 10-K on SEC EDGAR.